INTRODUCTION
The major histocompatibility complex (MHC) haplotype is the most significant genetic risk factor for human autoimmune diseases (ADs), thus drawing attention to T cells as major players of most immunopathological events (1) . T cells recognize antigen peptides associated to MHC (pMHC) through T cell antigen receptors (TCR), comprising a complex of two antigen recognition subunits (TCRa and TCRb) along with four signaling subunits (CD3g, CD3d, CD3e, and CD3z). Several control mechanisms exist to avoid activation of T cells bearing TCRs with high affinity for MHC loaded with self-peptides, including deletion of potentially autoreactive T cells during their maturation in the thymus. However, these mechanisms are overridden in AD patients, and selfreactive T cells become activated and expand (2) (3) (4) . Potentially autoreactive T cells are unable to cause disease when they emerge from the thymus because they must be activated by professional antigenpresenting cells (APCs) to differentiate into harmful effector T cells. T cells require three signals for this activation to take place: signal 1, derived from the TCR; signal 2, derived from costimulatory receptors, for example, CD28 upon binding to its ligands on APCs; and signal 3, derived from cytokine receptors responsible for T cell proliferation and differentiation (5) . Although the ultimate goal of therapeutic intervention in ADs is to stimulate immunological tolerance, the currently used agents seem more immunosuppressive than tolerogenic (6) . Methotrexate, mycophenolate, azathioprine, and cladribine are cytostatic drugs, whereas antibodies like alemtuzumab (anti-CD52) induce T cell depletion (7, 8) . Furthermore, despite the central importance of the TCR signal for T cell activation in ADs, most current efforts to restrain T cell activation concentrate on modulating the second and third signals mentioned above (6) . The anti-CD3 antibody OKT3 has been used successfully to treat acute rejection after allogeneic organ transplantation. However, this antibody induced severe adverse effects, such as cytokine release syndrome (9) . This phenomenon is due to the fact that OKT3 is not a TCR-blocking antibody but rather an agonistic one triggering the TCR. This illustrates the priority regarding safety for chronic diseases such as ADs, which requires fine-tuning of T cell activation to prevent autoimmune attacks without suppressing immune responses against infectious agents. Therefore, the development of immunomodulators, preferably small drugs, which can interfere with the TCR signal, is an issue that has yet to be adequately addressed.
The TCR translates small differences in the chemical composition of the pMHC into quantitatively and qualitatively distinct outcomes, although the mechanism underlying this process remains poorly understood. Upon triggering, the TCR becomes phosphorylated by Lck at several tyrosine residues in the cytoplasmic tails of the CD3 subunits. This phosphorylation generates docking sites for the Syk family tyrosine kinase ZAP70 (10) . However, ZAP70 is not the only direct effector of the TCR, and recruitment of other proteins has also been described, including that of Nck, RRas2, Grk2 (G protein-coupled receptor kinase 2), and PI3K (phosphatidylinositol 3-kinase) (10) (11) (12) (13) .
Nck is an adaptor protein that contains three tandem Src homology 3 (SH3) domains (SH3.1, SH3.2, and SH3.3) and a C-terminal SH2 domain. There are two highly similar Nck genes (Nck1 and Nck2) that are apparently redundant in terms of cell function (14, 15) . Nck universally coordinates signaling networks critical for actin cytoskeleton organization, cell movement, or axon guidance, connecting transmembrane receptors to multiple intracellular signaling pathways. Studies in double knockout mice lacking Nck1 in all tissues and conditionally lacking Nck2 in T cells set forth Nck as an important player in mature T cell function (16, 17) . In T cells, TCR triggering is followed by direct recruitment of Nck via its N-terminal SH3 (SH3.1) domain to a proline-rich sequence (PRS) in the cytoplasmic tail of CD3e (15, 18) . More recently, we have demonstrated in a genetic complementation test that Nck recruitment to the PRS appears functionally downstream of the conformational change that takes place in the TCR upon pMHC binding (19) . Experiments with Nck knockout mice and with mice bearing a mutated PRS indicate that the PRS-Nck interaction is important to activate mature T cells by weak but not strong agonists (17, 20) .
Here, we aimed to develop a new immunotherapy strategy for ADs by modulating TCR activation using a new small chemical inhibitor of the Nck-CD3e interaction. This inhibitor prevents full T cell activation in vitro with a median inhibitory concentration (IC 50 ) below 1 nM, precluding or mitigating symptoms in animal models of AD and inflammatory diseases after oral administration, while sparing the assembly of a protective response to a viral pathogen after vaccination.
RESULTS
A hit-to-lead process results in a potent modulator of T cell activation Nck is recruited through its SH3.1 domain to the PRS of CD3e (Fig. 1A ) (18) . The PRS of CD3e interacts with three shallow hydrophobic pockets in SH3.1 (21) (22) (23) . In CD3e, the canonical PxxP sequence involved in PRS-SH3 interactions is followed by two amino acids at position +3 that establish interactions with the third SH3.1 pocket (Fig. 1B , the DY pocket). Thus, the interaction sequence in the PRS of CD3e would be more accurately represented by the motif PxxPxxDY. Whereas the pockets for the two central proline residues are conserved in most SH3 domains (24) , the DY pocket is uncommon and has only been described in a handful of Eps8 family proteins (21, 25) . Furthermore, this pocket is constituted by aromatic and polar amino acid residues in the SH3.1 domain of Nck1 and Nck2 (Q20, Q22, E23, K39, T40, W41, and Y53 in Nck2), which are not found in other SH3 domains (table S1). We hypothesized that a high-affinity low-molecular weight compound that binds to the DY pocket might act as a selective inhibitor of the NckCD3e interaction. We set out to validate this hypothesis by means of a docking-based virtual screening approach performed on ligands from the ChemBridge database (www.chembridge.com/index.php) using our in-house platform (26) . The best score for each ligand was selected as the docking solution. Ten of the highest-scoring compounds were selected and tested experimentally through in vitro proliferation assays on human peripheral blood T cells stimulated with anti-CD3. Two compounds showed inhibitory properties at concentrations below 10 mM (Fig. 1C) , of which the most promising candidate was AX-000 ( Fig. 1D) , which was therefore selected as the hit for the hit-to-lead optimization process.
For optimization, we used the predicted fit of AX-000 in the DY pocket of SH3.1 ( fig. S1A ). According to this model, the 2H-benzopyran moiety sits at the bottom of the shallow DY pocket, establishing p-stacking interactions with the lateral chains of aromatic amino acids W41 and F53. AX-000 optimization was carried out by removing and adding substituents to the 2H-benzopyran moiety to subsequently compare the resulting compounds in human T cell proliferation assays. Molecular dynamics simulations suggested that the AX-000 phenyl substituent in position 2 is exposed to the aqueous solvent. This substituent hindered compound activity, whereas the piperidine substituent in position 3 of 2H-benzopyran favored its action (compare AX-000 with AX-0D9, AX-0A3, and AX-004; fig. S1 , A and B). Replacing the piperidine substituent by a smaller pyrrolidine ring and adding a methoxy substituent in position 6 gave rise to the lead compound AX-024, which was >10,000-fold more potent than the AX-000 hit in terms of inhibition of TCR-triggered T cell proliferation (Fig. 1, D and F) . The IC 50 of AX-024 in this assay was 1 nM, although it showed inhibitory effects at a concentration of 1 pM or less (Fig. 1F) . AX-024 was also a much more potent inhibitor of cytokine release by human peripheral blood mononuclear cells stimulated with anti-CD3 than AX-000, strongly hindering interleukin-6 (IL-6), tumor necrosis factor-a (TNFa), interferon-g (IFN-g), IL-10, and IL-17A production at a concentration of 10 nM (fig. S2) .
The molecular dynamics simulation of predicted AX-024 docking suggests that AX-024 occupies most of the cavity ( fig. S1C) . The cavity has a total volume of 718.4 Å 3 , of which 264.0 Å 3 is occupied by AX-024, roughly 37%. In contrast, the compound covers all the solvent-accessible surface area (SASA) of the pocket [the pocket has a SASA of 245.0 Å 2 , and AX-024 has a three-dimensional (3D) SASA of 522. 1 Å 2 ]. The interaction is prevalently through van der Waals' forces, except for a hydrogen bridge that is formed between the tertiary nitrogen of the pyrrolidine ring and the carbonyl group of the Q22 lateral chain (Fig. 1E) . The fluorophenyl group in position 4 is oriented toward K39, establishing hydrophobic interactions with the hydrocarbon region of the K39 side chain and with W41. The hydrocarbon moiety of the pyrrolidine group interacts via van der Waals forces with W41 and the methoxy group in position 6 with the hydrophobic part of K39. The methoxy group also reinforces the p-stacking interactions of the 2H-benzopyran nucleus with F53.
To demonstrate that AX-024 did indeed bind to the DY pocket of the Nck SH3.1 domain, we performed nuclear magnetic resonance (NMR) ligand/protein interaction studies using a double 13 C, 15 N-labeled sample of SH3.1(Nck1). The AX-024 hydrochloride salt was prepared to increase the compound solubility in water and was added to the protein sample (50 mM) at increasing protein/ligand ratios. Some cross peaks in the 2D 1 H, 15 N heteronuclear single-quantum coherence (HSQC) and 1 H, 13 C HSQC spectra of the SH3.1(Nck1) protein shifted upon titration (Fig. 1 , G and H; details of all amino acids are in fig. S3 ), confirming that AX-024 binds to this Nck domain. Because the NMR spectra of the SH3.1(Nck1) domain had been previously assigned (22) , we could identify which residues were affected by AX-024 binding and map the AX-024 binding site. The most substantial changes observed corresponded to the 1 H, 15 N cross peaks of the backbone amide groups of Q19, Q20, E21, E23, S38, K39, S40, W41, W42, and F53 (Fig. 1G) ; the side-chain amide groups of Q19, Q20, and Q22; and the 1 H, 13 C cross peaks of the side-chain protons of Q22, E23, and W41 (two selected regions of the spectrum are shown in Fig. 1H ). All these residues either contribute to the DY pocket (Q20, Q22, E23, S40, W41, and F53) or are very close to it (Q19, S38, and W42), and therefore, the NMR data confirmed that AX-024 bound to the DY pocket of the Nck SH3.1 domain. As expected, the residues showing shifts corresponded to only a fraction of those affected by binding of a CD3e peptide encompassing the entire PRS ( fig. S3 ), because the peptide not only binds to the DY pocket but also to the two pockets for the PxxP motif (Fig. 1B and fig. S3 ).
AX-024 specifically inhibits TCR-dependent T cell activation B cell antigen receptor (BCR) triggering also recruits Nck (27) . However, and unlike described previously for T cells, Nck recruitment to the BCR is mediated by the SH2 domain of Nck and is independent of the Nck SH3.1 domain. Consequently, BCR-triggered B cell proliferation [anti-immunoglobulin M (IgM) stimulation] was not inhibited by AX-024 at concentrations as high as 10 mM (Fig. 2A) . Likewise, B cell proliferation induced by the Toll-like receptor 4 (TLR4) and CD40 agonists LPS (lipopolysaccharide) and anti-CD40, respectively, was not inhibited. To determine whether the inhibitory effect of AX-024 on T cell activation is selective of stimuli that trigger the TCR, we evaluated its effects on the IL-2-dependent proliferation of T lymphoblasts, which is no longer dependent on TCR signaling. Neither AX-024 nor the parental compound AX-000 inhibited T lymphoblast proliferation at concentrations up to 10 mM (Fig. 2B) , suggesting that they did not inhibit general housekeeping activities in T cells. T cell proliferation induced by a combination of phorbol 12-myristate 13-acetate (PMA) and ionomycin, agents that bypass TCR signaling by activating downstream signaling pathways, was unaffected by AX-024, suggesting that AX-024 Tg T cells were WT for the PRS mutation (Fig. 2D ). In the absence of inhibitor, OT1 Tg PRS knock-in mouse T cells with a germline mutation in the PRS of CD3e (KI-PRS) that prevents Nck recruitment to the TCR (28, 29) proliferated nearly threefold less than WT OT1 Tg cells. However, incubation with AX-024 did not exert further inhibitory effects on T cell proliferation than those caused by the PRS mutation (Fig. 2D ), reflecting that AX-024 specifically targets the Nck-CD3e interaction.
The selectivity of AX-024 for the Nck-CD3e interaction is not surprising given that it targets an atypical pocket, that is, the DY pocket, which is only present in a few proteins of the Eps8 family, in addition to the SH3.1(Nck) domain (30) . One member of this family, Eps8L1, has been described to bind the PRS of CD3e (31) . However, the conservation of amino acid residues that make up the DY pocket (shown in red in table S1) is low in Eps8 family members as well as in all SH3 domains ( fig. S4A and table S1 ). The PRS is only exposed for SH3.1(Nck) binding when the TCR is triggered adopting the "open" conformation (18) . Thus, in a pull-down assay with an immobilized glutathione S-transferase (GST)-SH3.1(Nck) fusion protein, we noticed an increase in the abundance of TCR that is able to bind SH3.1(Nck) in lysates of T cells stimulated with anti-CD3 (Fig. 2E) . To assess the effect on binding of the entire TCR, Western blotting was carried out with an anti-CD3z antibody rather than with an antibody against the PRS-containing CD3e subunit, to avoid detection of nonassembled cytoplasmic CD3e. The inducible binding of the TCR through its PRS was also found when a GST-SH3(Eps8L1) recombinant protein was used in the pull-down assay ( Fig. 2E ), indicating that the inducible binding of SH3 domains to the PRS is a general property of the triggered TCR. However, although AX-024 inhibited TCR binding to SH3.1(Nck) with an IC 50 <0.1 mM in this assay, it did not affect binding to SH3(Eps8L1) ( To more precisely estimate the IC 50 of AX-024 inhibition of TCR binding to SH3.1(Nck), we carried out surface plasmon resonance (SPR) measurements of the binding kinetics of a synthetic peptide corresponding to the PRS of CD3e to an immobilized SH3.1(Nck1) domain. We injected CD3ewt peptide alone or in combination with different concentrations of AX-024 (0.1 to 100 nM) and detected an inhibitory effect even at low concentrations (Fig. 2F ). To estimate an IC 50 for the inhibition of CD3e peptide binding, we plotted the maximum steady-state response units at different AX-024 concentrations and found that it is about 1 nM (Fig. 2F) . A kinetic assay was performed with different concentrations of the CD3e peptide alone or in the presence of 0.1 to 100 nM concentrations of AX-024 to derive a K D of 7.5 mM for the peptide in the absence of drug and a 173-fold decrease in affinity in the presence of 1 nM AX-024 (Fig. 2F) .
We also determined whether AX-024 altered the recruitment of endogenous Nck to CD3e, and therefore to the TCR, in human blood T cells stimulated with anti-CD3. Coimmunoprecipitation experiments in these cells showed that Nck recruitment to the TCR was induced upon stimulation in the absence of drug but was inhibited in the presence of AX-024 in a dose-dependent manner at concentrations starting from 1 nM (Fig. 2G ).
AX-024 specifically inhibits the earliest TCR signaling events
Because Nck is a critical regulator of the actin cytoskeleton, we assessed whether AX-024 impaired its remodeling upon TCR triggering. Stimulating human blood T cells with anti-CD3 elicited a 2.5-fold increase of intracellular F-actin, which could be inhibited by AX-024 with an IC 50 of 1 nM (Fig. 3A) . By contrast, AX-024 did not affect fibroblast migration in a wound-healing assay, which itself is a process that depends on actin cytoskeleton rearrangement ( fig. S5 ). In addition, AX-024 inhibited phosphorylation of ZAP70 at Tyr 319 ( Fig. 3B ) and of CD3z at Tyr 142 ( Fig. 3C ), which represent two early hallmarks of TCR triggering. The inhibitory effect on tyrosine phosphorylation of CD3z was especially apparent for the low-mobility, fully phosphorylated form of the protein.
To explore the consequences regarding gene expression upon AX-024 inhibition of the TCR-Nck interaction, we carried out wholegenome microarray transcriptomic analysis of purified human blood T cells stimulated with anti-CD3 for 4 hours, and the experiment was repeated using T cells from two different blood donors. T cell stimulation in the presence of a concentration of AX-024 as low as 1 nM had an impact on gene transcription (Fig. 3D) . Although AX-024 treatment up-regulated the expression of a few genes compared to stimulated control cells, the effect of AX-024 was mostly to inhibit TCR triggering-induced gene expression. Precisely 1093 genes were transcriptionally downregulated in the presence of AX-024 in a reproducible manner, including genes that are relevant for inflammatory T cell responses, for example, cytokines IL-17A, IL-2, and IFN-g or cytokine receptors IL-6R and IL-18R1 (Fig. 3D ). An analysis of the impact of AX-024 treatment on mRNA expression using the Ingenuity Pathway Analysis software indicated that AX-024 was altering canonical pathways typically activated by proinflammatory cytokines (IL-15, IL-3, and IFN-g) and affecting transcription of genes involved in T helper (T H ) cell differentiation (Fig. 3E ). Gene expression analysis also allowed predicting upstream regulators affected by AX-024, including cytokines and tissue transglutaminase 2, a central mediator of inflammation (Fig. 3F ). The effect of AX-024 on gene expression also predicted that the drug was altering TCR (and CD3) signaling, thus reinforcing the biochemical and flow cytometry data in support of AX-024 inhibiting proximal TCR signaling. Furthermore, although we only used an anti-CD3 antibody for T cell stimulation in these experiments, that is, not including a CD28 ligand, the impact of AX-024 on gene expression pointed to an alteration of genes typically up-regulated by CD28 (Fig. 3F) .
The effect of AX-024 on the expression of a selected set of genes was also analyzed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in human T cells stimulated with anti-CD3 for 4 hours. Whereas the TCR-induced expression of some genes (for example, CXCL9, CXCL10, and EGR3; fig. S6 ) was abrogated at a concentration of 1 nM, the response of other genes was more gradual (for example, ZRANB2 and CD96) or even bimodal, with stronger inhibition at lower concentrations than at higher concentrations (for example, IL-2 and IFN-g; fig. S6 ). These results suggest that the effect of AX-024 on T cell activation is not a mere decrease in TCR signaling but rather results in a complex set of effects suggestive of immunomodulation.
AX-024 attenuates the severity of skin inflammation in a psoriasis model as well as of lung inflammation in an asthma model Before we tested the efficacy of AX-024 on animal models of ADs, we first tested acute toxicity in mice after a single intraperitoneal injection at four different doses (2.8, 14, 70, and 350 mg/kg). Mice followed for 14 days showed no significant adverse reactions to AX-024, and all mice gained weight at a similar rate ( fig. S7A ). Toxicity after singledose oral administrations was also evaluated in mice and rats. Single doses as high as 400 mg/kg (mice) or 1600 mg/kg (rats) were administered without any adverse effects on body weight ( fig. S7 , B and C), on organ size, or on the generation of lesions visible after necropsy ( fig. S7D ). These results showed that AX-024 administration was not toxic for rodents after single administration of doses as high 1600 mg/kg. As for thymocyte differentiation, it is impaired yet not blocked in mice bearing the germline mutation in the PRS of CD3e (KI-PRS) at every step in which pre-TCR or TCR signaling is required (29) . However, the administration of AX-024 for 10 days to 4-week-old mice did not have a significant impact on thymocyte subset numbers, suggesting that AX-024 does not seriously affect thymic differentiation ( fig. S8 ). 
Cell counts Cell counts
Upstream regulator P value Genes IL-2 5.03 10 -16 AMICA1, BCL2, CCL3L3, CD160, CD274, CDK4, CSF2, CTLA4, CXCL10, CXCL8, DENND2D, FASLG, GART, IFN-γ, IL-2,  IL-2RA, IRF4, KLRD1, KLRG1, LCP2, MLLT3, MYB, PDCD11, PHB, POLR1B, PTPRC, SOCS2, SOS1, TNF, TNFRSF9,  TNFSF10, TRAF1, ZBED2   Ionomycin   1.27 10 -15 BCL2, BCL2A1, CSF2, CTLA4, CXCL10, CXCL8, EGR1, EIF4G1, FASLG, GBP4, IFN-γ, IL-2, IL-2RA, IRF4, JARID2, NDFIP2,  NR4A1, SOCS2, TNF, TNFSF10   TCR   2.03 10 -14   +   AIM2, BCL2, BCL2A1, BTLA, CBLB, CCL3L3, CD27, CSF2, CTLA4, CXCL10, CXCL8, CXCL9, EGR1, F5, FASLG, GBP4,  IFN-γ, IL-2, IL-2RA, IRF4, LCP2, NR4A1, PTPRC, SLAMF1, SOCS2, STAT1, TNF, TNFSF13B, TXK   IFN-α   2.75 10 -14 AIM2, BCL2, BCL2A1, CSF2, CXCL10, CXCL8, CXCL9, DAXX, FASLG, GBP1, GBP2, IFI16, IFN-γ, IL-2, IL-2RA, IRF9, KLRG1,  NT5E, RNF31, SREBF2, STAT1, STAT2, TAP1, TAPBP, TNF, TNFSF10, TNFSF13B, TRIM22, TRIM5, TRIOBP, IGF1R, IL-2RA, IRF4, MYB, PHB, SERPINE2, SLAMF1, SP110, STAT1, TAP1, TFDP1, TNF, TNFSF10, TRIM22, TRIM5,   MAPK1   2.14 10 -11 BCL2, CCL3L3, CXCL8, EGR1, EXOC2, FASLG, GBP1, GBP2, GBP5, IFI16, IFIT5, IFN-γ, IL-2, IL-2RA, IRF9, MAST3, NT5E,  NUP188, OSBPL3, PTGER2, SOCS2, SP110, STAT1, STAT2, TAP1, TNF,TNFRSF9, TNFSF10, TRIM22, Psoriasis is a chronic inflammatory relapsing/remitting skin disease characterized by red, scaly, and often itchy patches, papules, and plaques that cover from small areas of the skin to the whole body (32) . We tested the effect of AX-024 on the prevention of parakeratosis, epidermal hyperplasia, and cellular infiltration after administration of the TLR7 and TLR8 agonist imiquimod (IMQ). Upon topical administration, IMQ reproduces many human psoriasis symptoms as well as IL-17 and IL-23 axis dependence (33, 34) . Mice received a daily topical dose of IMQ cream on their backs and their right ear for five consecutive days. A daily dose of AX-024·HCl (10 mg/kg) was administered orally for 5 days just before each IMQ administration, and the severity of inflammation of the back skin was scored on day 5. The AX-024-treated group presented less scales and reduced skin thickening compared to the vehicle group (Fig. 4A) . A more quantitative assessment of skin thickening was obtained by hematoxylin and eosin (H&E) staining of back skin sections and by subsequently measuring epidermal and dermal thickness at multiple sites chosen randomly. Treatment with AX-024 significantly reduced thickening of both skin layers, but more effectively of the dermis, which rather resembled that of mice treated with a control cream lacking IMQ (Fig. 4 , B and C). Epidermis thickening in the vehicle group correlated with an increase in the number of basal layer keratinocytes positive for the Ki67 marker of cells undergoing division (Fig. 4B, ×20 magnification, arrowhead) . The number of Ki67 + keratinocytes in the AX-024-treated group was reduced (Fig. 4B ), although this reduction was not statistically significant ( fig. S9A ). Higher magnification of H&E-stained sections highlighted the presence of areas of hemorrhage and intense infiltration with mononuclear and polymorphonuclear cells under the epidermis in the vehicle but not in the other two groups (Fig. 4B, ×20 magnification, arrowhead) . Furthermore, immunohistochemical staining with a Ly6G-specific antibody revealed numerous foci of infiltrating granulocytes that were localized subepidermally in the vehicle but not in the control or AX-024 groups [ Fig. 4B (×20 magnification, arrowhead) and fig. S9A ). Skin samples derived from mice in the vehicle group also presented with profuse scales that were positive for Ly6G staining (Fig. 4B, arrow) , whereas these were scanter in AX-024-treated mice (Fig. 4A, histogram) . Flow cytometry analysis after collagenase treatment was used to further evaluate skin infiltration by inflammatory cells. Treatment with AX-024 inhibited skin infiltration by granulocytes (Ly6G + cells), as well as by all CD11b + myeloid cells and by CD8 + T lymphocytes (Fig. 4D ). This reduced infiltration was accompanied by a strong reduction of proinflammatory cytokines (TNFa and IL-1b) and chemokines (CXCL2), as well as neutrophil chemoattractants (S100A8 and S100A9), as detected by qRT-PCR in skin samples (Fig. 4E and fig. S9B ). The cytokines IL-17A and IL-22 were not detectable in any condition. Together, these results indicate that AX-024 is effective at attenuating the psoriasis-like symptoms of inflammation in the IMQ model.
An animal model of ovalbumin (OVA)-induced allergic asthma was also used to test the prophylactic effect of AX-024. AX-024·HCl was administered twice, once with each OVA immunization (Fig. 5A ). After challenge with an aerosol of OVA, inflammatory cell recruitment to the lungs of immunized mice was examined in live animals 24 hours later by quantitative fluorescence molecular tomography (FMT) (Fig. 5B ) (35) and by postmortem evaluation of specific cell markers in the bronchoalveolar lavage fluid (BALF; Fig. 5C ). Whereas nonimmunized mice had negligible numbers of airway inflammatory cells in BALF, the immunized vehicle group had considerable numbers of inflammatory eosinophils, macrophages, and neutrophils (Fig. 5C ). Treatment with AX-024 significantly diminished the number of airway inflammatory cells in both assays. Allergic asthma is believed to be largely mediated by T H 2 cells (36), which are responsible for the secretion of IL-4, IL-5, and IL-13. Treatment with AX-024 significantly inhibited the release of IL-4 into BALF (Fig. 5D) . These results suggest that AX-024 treatment also prevents sensitization of mice to inhaled antigens in a model of allergic airway inflammation.
Oral administration of AX-024 prevents the development of neurological symptoms in a model of multiple sclerosis Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) that is estimated to affect 2.3 million people worldwide (37) . Experimental autoimmune encephalitis (EAE) is the most commonly used experimental model for MS, which is frequently induced by immunization with myelin-derived antigens in adjuvant to reproduce key pathological features of MS such as inflammation, demyelination, axonal loss, and gliosis (38) . To assess the capability of AX-024 to prevent EAE in C57BL/6 mice immunized with myelin oligodendrocyte glycoprotein (MOG ), we administered a single daily dose of AX-024·HCl (10 mg/kg) by oral gavage for 10 days, starting at the date of immunization. Treatment with AX-024 significantly diminished the neurological symptoms and weight loss induced by MOG immunization (Fig. 6A) . Mice receiving AX-024 rapidly recovered from neurological impairment and weight loss, becoming symptom-free by day 30, unlike mice that received the vehicle, in which ataxia and loss of the righting reflex persisted (Fig. 6A ). All mice in both groups were sacrificed at day 33 and analyzed for CNS infiltration. A massive infiltration of blood vessels and neural parenchyma by CD4 + T cells and macrophages was detected in the cerebellum and spinal cord of the vehicle group, but not of the AX-024-treated group (Fig. 6B) .
The effect of AX-024 was compared with that of an immunomodulatory drug currently used for MS treatment (glatiramer acetate) and with the immunosuppressor drug cladribine (39) , all administered in single daily doses for 10 days, starting on the day of MOG immunization. AX-024 was more effective than both control drugs in this prophylactic setting at preventing weight loss and neurological symptoms ( fig. S10 ).
AX-024 exerts a long-lasting therapeutic effect in the EAE model of MS
To assess whether AX-024 not only prevented EAE symptoms but also had a therapeutic effect in this MS model, we treated MOG-immunized mice with single daily doses of AX-024·HCl (10 mg/kg, oral administration) starting after disease onset on day 13, once the symptoms of neurological impairment (clinical score, ≥2) and weight loss were already evident (Fig. 6C) . A third group of mice was treated orally with fingolimod (0.6 mg/kg), a sphingosine 1-phosphate receptor (S1PR) modulator that has been approved as a first-line oral agent for the treatment of relapsing-remitting MS (40) . Both treated groups rapidly recovered from neurological symptoms and gained weight, although the fingolimod group reached a score of 0 one week earlier than the AX-024 group (Fig. 6C) . At day 26, drug treatment to both groups was discontinued, whereas scoring and weight were still monitored. By day 33, neurological symptoms and weight loss began worsening in the fingolimod group, reaching the values of the vehicle group by day 35. This outbreak of symptoms did not occur in the AX-024-treated mice, which maintained low clinical scores and kept gaining weight even up to day 52, 26 days after discontinuing the treatment (Fig. 6C) . These results suggest that AX-024 exerts a therapeutic effect that lasts even after the drug is no longer present.
AX-024 inhibits effector T H cell differentiation toward proinflammatory subsets
One possible mechanism by which AX-024 could exert its long-lasting effects is by altering T cell differentiation. Differentiation of naïve CD4 + T cells toward effector T cells not only depends on the presence of polarizing cytokines and their receptors but also on the signal strength of the TCR (41) . Because AX-024 inhibited but did not block the earliest TCR signals (Fig. 3C) , we could hypothesize that it altered the quality of effector cell differentiation. We found that 1 nM AX-024 inhibited the differentiation of human CD4 + T cells toward IFN-g-, IL-2-, and IL-17A-producing cells under T H 1-, T H 2-, and T H 17-polarizing conditions (Fig. 7A) . However, AX-024 treatment increased differentiation toward IL-4-producing and FOXP3 (forkhead box P3)-expressing cells under T H 2-favoring and T reg (regulatory T cell)-favoring conditions, respectively (Fig. 7A) . The lack of inhibition or even potentiation toward T H 2 cells in these ex vivo experiments is in contrast with the observed reduction of IL-4 in BALFs in the asthma model (Fig. 5D ), so we suspect that the discrepancy may be caused by the different milieu of the in vivo and ex vivo approaches. The prodifferentiation effect of AX-024 toward T reg was evident not only through the expression of markers but also in a functional assay of naïve CD4 + T cell proliferation ( 
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by altering the quality or strength of the TCR signal, AX-024 inhibits CD4 + T cell differentiation toward proinflammatory T cell populations while simultaneously favoring their differentiation toward anti-inflammatory effector subsets. CD4 + T cells differentiated under T H 1 conditions in the presence of AX-024 secreted less IFN-g and less TNFa to the culture supernatant in response to TCR triggering than in response to PMA + ionomycin, suggesting that a previous exposure to AX-024 conditioned TCR signaling in a permanent manner (Fig. 7D) .
AX-024 allows harnessing of an efficient memory T cell response against a mouse pathogen Considering that alteration of TCR signaling by AX-024 exerts a protective and therapeutic effect in the AD models described above, we wanted to assess whether this phenomenon was causing a concomitant, generalized immunosuppression. We immunized controls and mice treated with daily doses of AX-024·HCl (10 or 40 mg/kg) with the immunodominant poxvirus CD8 T cell epitope B8R and measured the antigendependent CD8 T cell response 7 days later, on the basis of IFN-g production. Neither dose of the drug significantly inhibited the activation of CD8 T cell response to the viral epitope (Fig. 8A) . We next tested whether AX-024 increased the susceptibility of mice to infection by the mouse pathogen ectromelia virus (ECTV), a poxvirus that causes a smallpox-like lethal disease in mice (mousepox). Resistance to this infection requires full assembly of innate and adaptive immune responses (43) . Drug-treated mice were given daily oral doses of AX-024 (10 and 40 mg/kg) that had demonstrated effectiveness in EAE and other models described herein for up to 10 days during and after infection with different doses of ECTV. All mice succumbed to a lethal dose of ECTV [10 5 plaque-forming units (PFU), intranasally (in)] but partly resisted infection with doses close to the median lethal dose (10 4 to 10 3 PFU, in; Fig. 8B , first challenge). AX-024 treatment did not influence survival rates to these sublethal doses nor to a lower dose (10 2 PFU, in), indicating that the drug did not increase sensitivity to infection in mice. To determine whether exposure to AX-024 during infection with a sublethal dose of ECTV altered the assembly of a functional memory response, we subjected all mice surviving the first challenge (Fig. 8B) to reinfection 60 days later with a lethal dose (10 5 PFU, in). All mice previously exposed to the virus resisted the lethal dose, regardless of their AX-024 treatment history, whereas a control group of naïve mice all succumbed to the infection (Fig.  8B, rechallenge) .
A protective memory response against ECTV requires both CD4 help, for an efficient humoral response, and CD8 T cell-mediated cytotoxicity (44) . To determine the presence of virus-responsive T cells, we analyzed the IFN-g response of CD8 T cells taken from maxillary lymph nodes of mice surviving rechallenge upon ex vivo stimulation with B8R. The percentage of responding cells from AX-024-treated . P values were calculated by Student' s t test. DAPI, 4′,6-diamidino-2-phenylindole. (C) The therapeutic effect of AX-024 was assessed in MOG-immunized mice by administering daily oral doses (10 mg/kg) of AX-024·HCl, starting on day 13 after immunization and ending on day 26 (temporal window of drug treatment indicated in the plot). Another group of mice received daily oral administrations of fingolimod (0.6 mg/kg) following the same schedule. Data represent means ± SEM (n = 10) of score and weight measurements. P values were calculated using the Kruskal-Wallis nonparametric test (red, AX-024 versus vehicle; blue, fingolimod versus vehicle). n.s., P > 0.05.
mice was indistinguishable from that of the vehicle group (Fig. 8C) . These results indicate that AX-024 does not prevent mice from establishing an effective memory response against a viral pathogen, further suggesting that the compound is not immunosuppressive. The mechanism for AX-024 selectivity on self-antigens versus pathogen-derived antigens is not completely understood, although a possible hint for its selectivity may be the differential requirement for Nck recruitment to the TCR in response to weak versus strong antigens (17, 20) . To interrogate a possible selectivity for weak antigens, we used the well-studied OT1 TCR transgenic system with its ample variety of antigen peptide derivatives (Fig.  8D ) (45) . As shown before in Fig. 2D , AX-024 inhibited OT1 T cell proliferation in response to the subthreshold weak agonist Q4H7 at picomolar concentrations, whereas much higher concentrations were required to inhibit T cell proliferation in response to the above-threshold agonist Q4R7 and the strong agonist OVAp (Fig. 8E) .
DISCUSSION
Here, we describe the discovery of a new type of immunomodulatory therapy that targets signal 1 for T cell activation (TCR signaling), exerting a prominent prophylactic and therapeutic effect in different models of ADs, while preserving T cell activation in response to pathogen-derived antigens. We targeted the druggable pocket in the SH3.1 domain of Nck using computational modeling and small-molecular weight compound libraries to subsequently validate the therapeutic potential of the lead compound in three animal models of ADs. Provided that the animal models used are sufficiently relevant for human disease, the differential effect of AX-024 on autoimmune versus infectious diseases would be expected to make patients less prone to immunosuppression and to opportunistic infections in the future. Because AX-024 targets the TCR signal, this inhibitor has the potential to become a broad-spectrum therapy for ADs and other inflammatory diseases. However, the present study still falls short of clarifying the mechanisms for the distinction between self-antigens and pathogen-derived antigens and of explaining the long-lasting effect of AX-024 in AD models once the drug is no longer present. Although Nck is a ubiquitous protein, the AX-024 inhibitor targets a noncanonical DY pocket in the SH3.1 domain formed by a constellation of residues that is unique to this domain. AX-024 did not inhibit binding of Eps8 family of proteins-the other only known family of proteins bearing a SH3 domain with a DY pocket-and, furthermore, did not inhibit the binding of c-Cbl to the SH3.1 domain of Nck (which does not involve the DY pocket). Further proof-of-target specificity is provided by the fact that incubation with AX-024 did not elicit additional inhibitory effects on the activation of T cells already deficient in the recruitment of Nck to the TCR. These features predict that AX-024 acts as a specific inhibitor of TCR-triggered T cell activation, an idea supported by the low acute toxicity of AX-024 in vivo and its potent inhibition of TCR-triggered T cell proliferation despite showing no inhibitory effect on T cell proliferation triggered by IL-2 or PMA + ionomycin. Hence, AX-024 does not apparently affect general cellular processes but rather acts as a selective inhibitor of TCR signaling. Target specificity is also suggested by the inhibition of TCR-triggered actin polymerization, an effect that is expected for an inhibitor that targets Nck recruitment and in line with the fundamental role of Nck as a scaffold for proteins involved in actin cytoskeleton remodeling (14, 15) . The fact that AX-024 directly targets TCR-associated signaling machinery is also reflected by the inhibition of TCR-triggered ZAP70 phosphorylation, another direct effector of the TCR, and the partial inhibition of CD3z phosphorylation. Because AX-024 inhibits Nck recruitment to the TCR, and given that TCR signals are central in the activation of the adaptive immune response, it would appear that AX-024 is an immunosuppressive agent rather than an immunomodulatory agent. However, Nck is required for the activation of T cells by weak but not strong antigens (17) , which seems to be the case for self-reactive T cells involved in the generation of ADs (2, 46, 47) . Similarly, PRS mutations in CD3e affect T cell responses to weak but not strong antigenic peptides (20) . This indicates that Nck recruitment to the TCR is critical for the activation of T cells bearing weakly reacting TCRs, such as those that have escaped negative selection in the thymus and are therefore weakly reactive against MHC loaded with self-antigens (2, 48) . We show that AX-024 inhibits OT1 T cell activation much more strongly in response to low-affinity than to high-affinity antigen peptides. This may be the reason why AX-024 does not render mice more sensitive to infection by ECTV or prevents the assembly of an efficient T cell memory response against it, because the virus bears high-affinity antigens.
We tested the therapeutic value of AX-024 in mouse models of psoriasis, allergic asthma, and MS, displaying a protective effect in all of them. Single daily oral administrations have prophylactic effects in the two models tested (psoriasis and EAE). More remarkable outcomes arise from comparing oral AX-024 and oral fingolimod administrations in a therapeutic setting in the EAE model. Both compounds showed a clear therapeutic effect, completely reducing the neurological score to 0. However, unlike mice treated with fingolimod, mice treated with AX-024 did not worsen after drug removal, indicating that AX-024 has a long-lasting therapeutic effect. From a mechanistic point of view, the comparison between the effects of fingolimod and AX-024 is especially intriguing. Fingolimod is believed to prevent T cell egress from the lymph nodes, and thereby CNS infiltration, by modulating the chemotactic receptor S1PR (40) . This effect is dependent on the continuous presence of the drug, such that interruption of the treatment allows T cells to infiltrate the CNS, causing a rapid and severe relapse (49) . By contrast, the therapeutic effect of AX-024 persisted after removing the drug, suggesting that exposure to AX-024 induces a persistent modification of autoimmune T cells.
One of the repercussions of TCR signal alteration seems to be the differential effect of AX-024 on the in vitro differentiation of CD4 + T cells toward proinflammatory, IFN-g-producing, and IL-17A-producing effector cells, while favoring differentiation to T reg . These data suggest that, by inhibiting Nck recruitment to the TCR with AX-024, it is possible to differentially affect intracellular signaling pathways rather than the overall signal intensity, leading to a differential effect on the capacity of T cells to differentiate into effector T cells. The hypothesis that conventional effector CD4 + T cells (T H 1, T H 2, and T H 17) can be inhibited without affecting T reg activity was recently proven in genetically modified mice bearing a germline mutation in ZAP70 that makes this kinase sensitive to a small-molecule inhibitor (50) . Unfortunately, a highly specific, cell-permeable inhibitor of ZAP70 suitable for treatment against human disease has yet to be reported, which sets forth AX-024 as the first inhibitor of a direct TCR effector that could be used in clinical trials. Thus far, an Investigational Medicinal Product Dossier has been issued and approved for clinical tests in human volunteers, and phase Ia/Ib clinical trials have already been conducted (https://clinicaltrials.gov/ct2/show/NCT02243683?term= Artax&rank=2; https://clinicaltrials.gov/ct2/show/NCT02546635?term= Artax&rank=1).
We should highlight that AX-024 is not an inhibitor of an enzymatic activity but rather disturbs a protein-protein interaction. To the best of our knowledge, there is no other cell-permeable small-molecule inhibitor that acts by binding to an SH3 domain. Therefore, AX-024 represents a first-in-class inhibitor that modulates cell signaling by targeting SH3 domains and in turn is a first-in-class inhibitor of TCR signals. Finally, the low-acute toxicity profile of AX-024 and its high potency and selectivity, together with the fact that it targets TCR signals, make AX-024 a candidate for evaluation as an oral drug in clinical trials of psoriasis, MS, and, presumably, many other ADs.
MATERIALS AND METHODS

Study design
The aim of this study was to show whether recruitment to the TCR of Nck through the PRS of CD3e was a pharmacologically amenable target for the treatment of T cell-mediated diseases. The sample sizes chosen for the drug treatment were adequately designed to observe the effects on the basis of past experience and studies of this type conducted by others. Animals were only excluded in case of an accident during immunization or if drug administration resulted in severe damage. Mice and rats receiving vehicle or drugs were randomized after immunization. The identity of the animals that received vehicle or drugs was masked to researchers who scored them. The identity was revealed after the data had been collected. Details on sampling and experimental replicates are provided in each figure legend.
Virtual screening
Putative ligands for virtual screening were obtained from the publicly available ChemBridge database in SMILES format (51) , and they were processed with our in-house VSDMIP platform according to our standard protocol (26, 52) . Further information regarding chemical library preparation, receptor preparation, binding site characterization, virtual screening, and molecular modeling of AX-024 is described in the Supplementary Methods.
Synthesis of 2H-benzopyran derivatives 2H-benzopyran derivatives were synthesized as described in the Supplementary Methods.
NMR spectroscopy NMR experiments were performed as described in the Supplementary Methods.
Surface plasmon resonance SPR was performed on a Biacore X Instrument (General Electric) setup according to the manufacturer's instructions, using CM5 as a sensor chip. For immobilization and interaction details, see the Supplementary Methods.
Cells and mice
Human blood samples were obtained from the Center for Blood Transfusions of the Comunidad de Madrid, where donations were obtained from healthy volunteers after providing their informed consent. Murine lymph node T cells were maintained in RPMI and 10% fetal bovine
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serum supplemented with 20 mM b-mercaptoethanol and 10 mM sodium pyruvate. All mice were maintained under specific pathogen-free conditions at the animal facilities of the Centro de Biología Molecular Severo Ochoa, the Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, or the Instituto de Investigaciones Biomédicas August Pi i Sunyer, in accordance with current national and European guidelines (Directive 2010/63/EU). All animal procedures were approved by the ethical committees of the three institutes.
T cell proliferation
Human T cell proliferation in response to anti-CD3 was measured by CFSE dye dilution. Fresh human peripheral blood lymphocytes (PBLs) were obtained by density centrifugation of whole blood, labeled with 4 mM CFSE and incubated for 4 days at 37°C on anti-CD3 antibody OKT3-coated 96-well plates in the presence of inhibitors. Alternatively, fresh human PBLs were CFSE-labeled and stimulated for 4 days at 37°C with a mixture of PMA (10 ng/ml) and 1 mM ionomycin in the presence of inhibitors. Cells were stained with APC-labeled anti-CD4 and analyzed in a FACSCalibur flow cytometer. The proliferation index was calculated according to the number of cell divisions and the percentage of cells in each CFSE peak of the CD4 + population. Human T cell lymphoblasts were generated from PBLs by stimulation with phytohemagglutinin (2 mg/ml) in RPMI with 10% fetal bovine serum. After 2 days, the cultures were washed and expanded in medium with IL-2 for 5 days. Human lymphoblasts were subsequently washed, labeled with CFSE, and stimulated with IL-2 (100 ng/ml) for 3 days further in the presence of inhibitors.
Human T cell proliferation in response to PMA + ionomycin was analyzed by [ 3 H]thymidine incorporation 48 hours after stimulation with PMA (10 ng/ml) and ionomycin (1 mM) in the presence of the indicated concentrations of AX-024.
Lymph node T cells from OT1 TCR transgenic WT or PRS knock-in mice (KI-PRS) (28) were labeled with CellTrace Violet (Life Technologies), incubated for 1 hour in the presence of different concentrations of AX-024, and subsequently stimulated for 3 days with bone marrowderived dendritic cells (DCs) preloaded with different peptide antigens at a ratio of 1.5 × 10 5 T cells/3 × 10 4 DCs. DCs were preloaded with either the agonist OVA peptide (SIINFEKL) (100 pM) or the OVA peptide variant Q4H7 (SIIQFEHL) (10 nM). At the time of analysis, cells were stained with anti-CD8-peridinin chlorophyll protein and anti-CD25-APC antibodies (BD Pharmingen). Cell proliferation was analyzed by CellTrace Violet dilution as described above for CFSE dilution.
B cell proliferation
Spleen B cells from C57BL/6 mice were labeled with CellTrace Violet and incubated for 72 hours with either anti-IgM (10 mg/ml) or anti-CD40 (5 mg/ml), supplemented with IL-4 (5 ng/ml) or LPS (2.5 mg/ ml) in the presence of different concentrations of AX-024. Proliferation was calculated according to the total number of cell divisions (by CellTrace Violet dilution).
Differentiation of human T H cells in vitro
Naïve human blood CD4 + T cells were activated with plate-bound anti-CD3 (5 mg/ml), anti-CD28 (5 mg/ml), and different cytokine and antibody cocktails for 3 days, washed, and cultured for two additional days in the absence of CD3 and CD28 stimulation under conditions described in the Supplementary Methods. Five days after activation, the cells were washed and restimulated for 4 hours with PMA and ionomycin in the presence of GolgiStop. Intracellular expression of IL-17A, IFN-g, IL-4, IL-2, and FOXP3 and extracellular expression of CD25 were analyzed after staining with specific antibodies.
Cytokine release
Fresh human T cells enriched from whole blood as described in the Supplementary Methods were used to measure secreted cytokines using a BD CBA kit.
Immunoblot analysis of T cell activation A total of 3 × 10 7 enriched human T cells were stimulated with soluble OKT3 anti-CD3 antibody (10 mg/ml) for different times or stimulated with Raji APC cells, lysed, and analyzed by Western blot, as described in the Supplementary Methods.
Microarray analysis of gene expression
Microarray analysis of gene expression is described in the Supplementary Methods.
Acute toxicity
Eight-week-old CD-1 mice were injected intraperitoneally with different amounts of the hydrochloride salt of AX-024 (AX-024·HCl) dissolved in 0.5 ml of saline. All animals were observed clinically for the appearance of macroscopically visible adverse reactions twice daily over 14 days, as well as immediately after AX-024 administration. A necropsy was carried out on each animal on day 14, and the abdominal, thoracic, and cranial cavities were examined in situ, together with their associated organs.
Experimental autoimmune encephalomyelitis
All these studies were approved by the Ethics and Scientific Committees of the University of Barcelona. Chronic EAE was induced in female C57BL/6 mice (6 to 8 weeks old; 20-g body weight) by subcutaneously injecting a total of 150 mg of MOG (Espikem) emulsified in Freund's complete adjuvant (Sigma-Aldrich) and supplemented with Mycobacterium tuberculosis (1 mg/ml) (H37Ra strain from Difco) into both femoral regions. The mice were immediately injected intraperitoneally with 200 ng of pertussis toxin (Sigma-Aldrich) and, again, 48 hours after immunization. The animals were weighed and inspected for clinical signs of disease on a daily basis by an observer blind to the treatments. Disease severity of EAE was assessed according to the scale described in the Supplementary Methods. At the end of the study, the animals were anesthetized and perfused intracardially with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.6). The brains and spinal cords of the mice were dissected out and fixed. Daily doses of AX-024 (0.01, 0.1, and 1 mg per mouse per dose), glatiramer acetate (0.1 mg per mouse per dose), and cladribine (0.02 mg per mouse per dose) were prepared in phosphate-buffered saline (PBS) and administered intraperitoneally. In the prevention trials, treatments were given for 10 days starting on the day of immunization, whereas in the therapeutic trial, the treatment began when more than 50% of the animals reached a score higher than 2 and was administered until the end of the experiment. Histological and immunohistochemical evaluations are described in the Supplementary Methods.
IMQ model of psoriasis BALB/c mice were purchased from Harlan and kept under specific pathogen-free conditions with food and water ad libitum. All experimental procedures were approved by the local animal ethics committee according to Spanish and European guidelines. The IMQ-induced model of psoriasis was conducted following the protocol described by van der Fits et al. (34) and in the Supplementary Methods. Flow cytometry analysis of psoriatic skin was performed on mouse ears, and the scoring severity of mouse back skin inflammation was assessed as described in the Supplementary Methods. Immunohistochemistry and cytokine expression analyses were carried out on mouse back skin following the protocols described in the Supplementary Methods.
OVA-induced allergic asthma model BALB/c mice (10 to 12 weeks old) were injected with OVA (15 mg, ip) (Sigma) in 200-ml alum (Pierce). The injection was repeated on days 5 and 12, and mice were challenged with aerosolized 0.5% OVA in PBS (two 60-min challenges administered 4 hours apart). Control animals were exposed to inhaled PBS alone. AX-024·HCl was injected intraperitoneally on days 0 and 5, 2 hours before OVA administration. Mice were sacrificed on day 14, 40 hours after the aerosol OVA challenge, and BALF was collected or analyzed in vivo by FMT imaging on day 13. When analyzing BALF, different populations of leukocytes were identified by their expression of CD11b, Gr-1, B220, and CD11c. IL-4, IL-5, and other effector T cell cytokines were measured in BALF supernatants with a FlowCytomix Mouse T H 1/T H 2 10plex kit (Bender MedSystems GmbH), followed by flow cytometry in BD FACSCanto II Cytometer (BD Biosciences). In Vivo FMT 1500 Tomographic Imaging was performed as described in the Supplementary Methods.
Ectromelia infection
The reference ectromelia strain used was ECTV-Naval.Cam (complete genome sequence available at www.poxvirus.org). ECTV was grown in BSC-1 cells. For infection of mice, virus stocks were purified by centrifugation through a 36% sucrose cushion. Four-to 6-week-old female C57BL/6 mice were obtained from Harlan laboratories, and housed in filter-top microisolator cages in an animal biosafety level 3 containment area. Animal husbandry and experimental procedures were in accordance with Public Health Service policy and approved by the Institutional Animal Care and Use Committee. Details regarding ECTV injection and AX-024 treatment are described in the Supplementary Methods.
Statistical analyses
Data are reported as means ± SEM of multiple individual experiments each carried out in triplicate. Unless stated otherwise, the statistical analysis was carried out with GraphPad Prism 6.0. A two-tailed t test was used if two groups were compared, and a nonparametric Kruskal-Wallis test was used when three groups were simultaneously compared. Differences were considered significant if P < 0.05. For SPR data, statistical analysis was performed with MathLab v7.8 (2009) software, considering a normal distribution for each data set (k on and k off ) per feature and per assay, and using a median absolute deviation to gain a robust measure of the statistical dispersion of the data obtained. The values (k on and k off ) outside of the criteria (average ± 3 SD) were removed, and the affinity constant (K D ) was established as k off /k on values.
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